Key Takeaway
Tirzepatide produces greater average weight loss than semaglutide in clinical trials, but semaglutide has a longer track record and more affordable compounded options available.
Semaglutide achieves 14.9% weight[1] loss at 68 weeks in STEP 1[1] trials while providing unique cardiovascular protection with 20% MACE reduction in the SELECT trial[2]. Tirzepatide produces superior weight loss at 22.5% but lacks cardiovascular outcomes data. Semaglutide offers broader compounded availability, a longer safety track record since 2021, and proven heart benefits that make it competitive despite lower weight loss numbers.
How They Work
Semaglutide
Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone to suppress appetite, slow stomach emptying, and improve blood sugar regulation. It's available as Wegovy (for weight management) and Ozempic (for type 2 diabetes), as well as in compounded formulations compounded vs brand semaglutide.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It targets two incretin hormones instead of one, which may explain its stronger weight loss effect. It's sold as Zepbound (for weight management) and Mounjaro (for type 2 diabetes) .
Semaglutide Clinical Evidence
Semaglutide functions as a GLP-1 receptor agonist, delaying gastric emptying by 30-40% and reducing appetite through hypothalamic signaling. The medication requires weekly dosing from 0.25mg escalating to 2.4mg maintenance over 16-20 weeks. Side effects occur predictably with nausea in 44% of patients and diarrhea in 30%, typically resolving within 8-12 weeks of dose stabilization.
View data table
| Category | Search Volume Share (%) | Detail |
|---|---|---|
| Side Effects | 35 | Nausea, GI issues |
| Cost/Insurance | 28 | Pricing questions |
| Effectiveness | 22 | How much weight loss |
| Eligibility | 15 | BMI requirements |
The STEP trial program establishes semaglutide's efficacy across multiple populations. STEP 1 demonstrated 14.9% weight[1] loss in 1,961 participants[1] at 68 weeks, with 32% achieving 20% or greater weight reduction. The landmark SELECT cardiovascular trial in 17,604 participants showed 20% reduction in major adverse cardiovascular[2] events, positioning semaglutide as the only GLP-1 agonist with proven heart protection data for weight management patients.
Cardiovascular Advantage
SELECT trial results give semaglutide a unique advantage with 20% reduction in heart attacks, strokes, and cardiovascular death over 3.3 years. Tirzepatide's cardiovascular outcomes trial (SURPASS-CV[2]OT) remains ongoing with results expected in 2024.
Head-to-Head Comparison
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Average weight loss | ~15% of body weight | ~20-22.5% of body weight[3] |
| Mechanism | GLP-1 agonist | Dual GIP/GLP-1 agonist |
| Administration | Once-weekly injection | Once-weekly injection |
| Cardiovascular data | SELECT trial: 20% CV risk reduction | CV outcomes trial ongoing |
| Brand-name cost | ~$1,300/month $1,300-$1,400/mo (brand) | ~$1,100/month $1,000-$1,200/mo (brand) |
| Compounded availability | Widely available | More limited |
| Years on market | Since 2021 (Wegovy) | Since 2023 (Zepbound) |
Weight Loss Effectiveness
For raw weight loss, tirzepatide has the edge. The SURMOUNT-1 trial[3] showed an average of 22.5% body weight[3] reduction at the highest dose over 72 weeks . The STEP 1 trial showed 14.9% with semaglutide over 68 weeks . For a complete cost breakdown, see our best tirzepatide compounding pharmacies.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →
A head-to-head study (SURPASS-2[4]) comparing tirzepatide to semaglutide in type 2 diabetes patients found that tirzepatide produced greater weight loss at all dose levels . But individual results vary significantly, and some patients respond better to semaglutide than tirzepatide.
Safety and Side Effects
Both medications share similar GI side effects, including nausea, diarrhea, constipation, and vomiting. These are typically most pronounced during dose escalation and tend to improve over time .
Semaglutide has a notable advantage in cardiovascular safety data. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events . Tirzepatide's dedicated cardiovascular[2] outcomes trial is still underway, though early indicators are positive.
Cost and Accessibility
Semaglutide currently has a significant advantage in accessibility through compounded formulations. Compounded semaglutide is widely available through platforms like FormBlends at a fraction of the brand-name cost Contact provider for current pricing. Compounded tirzepatide options are more limited, though availability continues to evolve cheapest way to get semaglutide.
Which Should You Choose?
Consider semaglutide if:
- Cost is a significant factor and you want access to compounded options
- You have cardiovascular risk factors and value the SELECT trial data
- You prefer a medication with a longer real-world track record
Consider tirzepatide if:
- Maximizing weight loss is your primary goal
- You haven't responded adequately to semaglutide
- You have type 2 diabetes and want stronger blood sugar control
Your provider can help determine the best fit based on your health history, goals, and budget FormBlends consultation.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. [PubMed | DOI]
Frequently Asked Questions
Can I switch from semaglutide to tirzepatide?
Yes, switching is possible and sometimes recommended when patients plateau on semaglutide or want to try a dual-agonist approach. Your provider will typically start tirzepatide at a low dose to manage side effects during the transition .
Does tirzepatide have more side effects than semaglutide?
The side effect profiles are similar. Some studies suggest slightly higher rates of GI symptoms with tirzepatide at the highest doses, but the difference is modest and both medications are generally well tolerated .
Is tirzepatide available in compounded form?
Compounded tirzepatide availability varies and depends on FDA shortage designations and regulatory factors. Compounded semaglutide is currently more widely accessible. Check with platforms like FormBlends for the latest options.
Can you take semaglutide and tirzepatide together?
No. Semaglutide and tirzepatide shouldn't be taken together. Since tirzepatide already activates the GLP-1 receptor, adding semaglutide would provide no additional benefit and could increase the risk of side effects .
Which medication works faster for weight loss?
Both medications begin working within the first week or two. Noticeable weight loss typically occurs within 4 to 8 weeks for both. Tirzepatide may show a slightly faster rate of loss due to its dual mechanism, but the difference in early weeks is small how fast does semaglutide work.